Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
FAQs
Maravai Lifesciences Holdings (MRVI) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com? ›
Average Price Target
Who are the competitors of Maravai Life Sciences? ›The main competitors of Maravai LifeSciences include Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Summit Therapeutics (SMMT), Viking Therapeutics (VKTX), ...
Who are the shareholders of Maravai Life Sciences? ›Largest shareholders include Gtcr Llc, 12 West Capital Management LP, Vanguard Group Inc, Braidwell Lp, BlackRock Inc., Millennium Management Llc, Mackenzie Financial Corp, Marshall Wace, Llp, Massachusetts Financial Services Co /ma/, and AASCX - Thrivent Mid Cap Stock Fund Class A .
What is the tipranks forecast for ai stock? ›AI Stock 12 Month Forecast
Based on 11 Wall Street analysts offering 12 month price targets for C3ai in the last 3 months. The average price target is $32.33 with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 11.33% change from the last price of $29.04.
RNXT Stock 12 Month Forecast
Based on 1 Wall Street analysts offering 12 month price targets for RenovoRx in the last 3 months. The average price target is $3.50 with a high forecast of $3.50 and a low forecast of $3.50.
Maravai Lifesciences Holdings's analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
What does Maravai Life Sciences do? ›We set the standard in nucleic acid products, services and biologics safety testing throughout the development process. We offer our customers the unique combination of speed and flexibility, along with the robust capability to scale up and scale out.
How many employees does Maravai have? ›How many employees does Maravai LifeSciences have? As of September 30, 2022, we employed a team of over 600 employees. Where can I find out more about Maravai LifeSciences? To learn more about Maravai LifeSciences please visit our website at www.maravai.com.
Who is the CEO of Maravai? ›Trey Martin
Prior to assuming the CEO role in July 2023, Mr. Martin served as President, Biologics Safety Testing at Maravai from December 2022 to July 2023.
All shares of Class A common stock are being offered by Maravai. The shares are expected to begin trading on the Nasdaq Global Select Market on November 20, 2020, under the symbol “MRVI.” The offering is expected to close on November 24, 2020, subject to the satisfaction of customary closing conditions.
What are the best AI stocks to buy now? ›
| Ticker | Company | Performance (Year) |
|---|---|---|
| NVDA | NVIDIA Corp | 217.58% |
| AVAV | AeroVironment Inc. | 133.61% |
| PRCT | Procept BioRobotics Corp | 78.93% |
| HLX | Helix Energy Solutions Group Inc | 55.56% |
ai's stock price in 2025. Opinions on C3. ai's future stock price are varied across different sources: According to Yahoo Finance, the median 12-month forecast for C3.ai is $115, with a high estimate of $166 and a low estimate of $572.
How much is the AI market worth in 2025? ›UBS predicted that the artificial intelligence hardware and services market will hit $90 billion by 2025. It was worth around $36 billion in 2020, per IDC and Bloomberg Intelligence data.
What is the stock price forecast for Gehc in 2025? ›According to analysts, GEHC price target is 93.10 USD with a max estimate of 105.00 USD and a min estimate of 86.00 USD.
What is the DBGI stock forecast for 2025? ›According to analysts, DMGI price target is 1.00 CAD with a max estimate of 1.00 CAD and a min estimate of 1.00 CAD.
What is the target price for ATNX? ›Average Price Target
Based on 2 Wall Street analysts offering 12 month price targets for Athenex in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 884.74% change from the last price of $0.20.
Advanced Fertility Care, Genetics & Ivf Institute, The Fertility Partnership, Kindbody, and CNY Fertility are some of the 8 competitors of Generate Life Sciences.
Who are the competitors of TMRW Life sciences? ›- TMRW.
- Quality Chemical Laboratories.
- Foundation Medicine.
- Trans Genic.
- Cogstate.
- BioIVT. 368 $100M$1B.
- Sartorius. 9K $1B.
- Medpace. 5.6K $1B.
- Charles River Laboratories. 15K $1B.
- Crown Bioscience. 597 $100M$1B.
- Syneos Health. 23K $1B.
- IQVIA. 74K $1B.
- PPD. 27K $1B.
Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%; and. Introduced full year 2024 revenue guidance range of $265.0 million to $285.0 million.